首页> 美国卫生研究院文献>Scientific Reports >Deficiency in catechol-o-methyltransferase is linked to a disruption of glucose homeostasis in mice
【2h】

Deficiency in catechol-o-methyltransferase is linked to a disruption of glucose homeostasis in mice

机译:儿茶酚-o-甲基转移酶的缺乏与小鼠体内葡萄糖稳态的破坏有关

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

2-methoxyestradiol (2-ME), an estrogen metabolite generated via catechol-o-methyltransferase (COMT), is multifunctional methoxy-catechol. Here, we report that COMT deficiency leads to glucose intolerance and 2-ME rescues COMT-deficient-associated metabolic defects. Liver COMT protein was suppressed in high fat diet (HFD)-fed or in pregnant mice. COMT suppression, by Ro41-0960 or siRNA, in HFD fed mice or in pregnant mice exacerbated glucose intolerance; 2-ME intervention ameliorated these defects. 2-ME effects on glucose tolerance were associated with AMPK phosphorylation in the liver and in islet cells. Metformin restored liver COMT protein levels, and metformin-induced liver AMPK phosphorylation was abolished by COMT inhibition. The amelioration in glucose tolerance by 2-ME was associated with biphasic insulin secretion in an environment-dependent manner. 2-ME-induced insulin secretion was associated with the AMPK phosphorylation, PDX-1 phosphorylation, and MST-1 suppression in MIN-6 cells. Furthermore 2-ME displayed PPARγ agonist-like activity. These results suggest that COMT is an enzyme to maintain glucose homeostasis and 2-ME is a potential endogenous multi-target anti-diabetic candidate.
机译:通过邻苯二酚-邻甲基转移酶(COMT)生成的雌激素代谢物2-甲氧基雌二醇(2-ME)是多功能甲氧基-邻苯二酚。在这里,我们报告COMT缺乏症导致葡萄糖不耐症和2-ME挽救COMT缺乏症相关的代谢缺陷。在高脂饮食(HFD)喂养或怀孕的小鼠中,肝脏COMT蛋白被抑制。 Ro41-0960或siRNA对HFD喂养的小鼠或妊娠小鼠的COMT抑制加剧了葡萄糖耐受不良。 2-ME干预改善了这些缺陷。 2-ME对葡萄糖耐量的影响与肝脏和胰岛细胞中AMPK磷酸化有关。二甲双胍可恢复肝脏COMT蛋白水平,而COMT抑制作用可消除二甲双胍诱导的肝脏AMPK磷酸化。 2-ME改善的葡萄糖耐量与环境相关的双相胰岛素分泌有关。 2-ME诱导的胰岛素分泌与MIN-6细胞中的AMPK磷酸化,PDX-1磷酸化和MST-1抑制有关。此外2-ME显示出PPARγ激动剂样活性。这些结果表明COMT是维持葡萄糖稳态的酶,而2-ME是潜在的内源性多靶点抗糖尿病候选药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号